Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction
June 01, 2022
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin…
Read More
COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD
May 31, 2022
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease
May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and…
Read More
First clinical data of implantable heart sensor with remote measurement capabilities presented at prestigious Late-Breaking Science forum at the ESC Heart Failure 2022
May 31, 2022
VECTOR-HF I Study Confirms Safety and Accuracy of V-LAP In-Heart Sensor for Left Atrial Pressure Management of Heart Failure
May 31, 2022 — Vectorious Medical Technologies Ltd., an innovator in implantable hemodynamic monitoring in heart…
Read More
Clearance paves the way for brand-new savings opportunities for cath labs nationwide
May 31, 2022
Innovative Health Expands into Cath Lab with Clearance to Reprocess Eagle Eye Digital IVUS Catheter
May 31, 2022 —  Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received…
Read More
Built on the market-leading IN.PACT Admiral DCB technology, the IN.PACT 018 DCB is engineered to cross tight lesions and designed for better deliverability
May 27, 2022
Medtronic Announces FDA Approval for IN.PACT 018 PTA Balloon Catheter
May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018…
Read More
The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES).
May 27, 2022
MedAlliance’s SELUTION SLR Drug-eluting Balloon Receives FDA Investigational Device Exemption Approval
May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a…
Read More
The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has identified this as a Class I recall, the most serious type of recall.
May 26, 2022
Abbott Medical Recalls Dragonfly OpStar Imaging Catheter for Potential Loose Catheter Marker Band
May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has…
Read More
At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power of artificial intelligence, and Sheba Medical Center Israel revealed new research findings from a blinded pilot study that validates the company’s technology, and confirms that UltraSight’s Artificial Intelligence (AI) guidance can allow any medical professional to successfully capture quality cardiac ultrasound images.
May 26, 2022
New Study Reveals UltraSight & Sheba Medical Center Enable Novice Ultrasound Users to Obtain Accurate, Diagnostic Quality Cardiac Images
May 26, 2022 — At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health…
Read More
Late-breaking results presented at the European Society of Cardiology's Heart Failure Association annual conference and simultaneously published online in the European Journal of Heart Failure
May 26, 2022
Axon Therapies Announces Positive Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
May 26, 2022 — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced…
Read More
The study found a gene called FMNL2 links cerebrovascular disease and Alzheimer’s and suggests changes in FMNL2 activity caused by cerebrovascular disease prevent the efficient clearance of toxic proteins from the brain, eventually leading to Alzheimer’s disease.
May 26, 2022
Missing Link Between Alzheimer's and Vascular Disease Found?
May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol…
Read More
Immune response and the lymphatic system are central to cardiac repair after a heart attack, according to a study from Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg Cardiovascular Research Institute.
May 25, 2022
New Research Reveals How the Heart Repairs After a Heart Attack
May 25, 2022 — Immune response and the lymphatic system are central to cardiac repair after a heart attack, according…
Read More
A section of a normal healthy heart (left) and three locations in a heart from a patient with arrhythmogenic cardiomyopathy. There are a lot more fat cells (large while spheres) in the diseased heart. Cardiomyocytes in the composite region often show signs of degeneration, as well as enhanced ZBTB11 expression
May 25, 2022
New Gene Identified in Arrhythmogenic Cardiomyopathy
May 25, 2022 — Researchers from the group of  Eva van Rooij used advanced sequencing technology to better understand…
Read More
The ĹŚNĹŚ is intended to simplify bailout procedures in the expanding world of structural heart disease interventions
May 25, 2022
ĹŚNĹŚCOR Receives FDA Clearance for Novel Endovascular Retrieval Technology
May 25, 2022 — ŌNŌCOR LLC, a leader in endovascular safety technology, today announced it has received 510(k) U.S. Food…
Read More
Thomas E. MacGillivray, MD
May 25, 2022
Thomas E. MacGillivray Named Chair of Cardiac Surgery for MedStar Heart & Vascular Institute
May 25, 2022 — MedStar Heart & Vascular Institute announced that Thomas E. MacGillivray, MD, has been named…
Read More
Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022
May 24, 2022
Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events
May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost-…
Read More
Continued research into efficacy of ensoETM for RF ablation procedures will support future regulatory efforts for expanded indications
May 24, 2022
First Patients Enrolled in IMPACT II Study
May 24, 2022 — Attune Medical, a pioneering medical device company with a technology platform based on temperature…
Read More
The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has initiated a voluntary nationwide recall of a single lot of Anagrelide Capsules, USP 0.5 mg (Lot number GD01090), to the consumer level in the United States.
May 24, 2022
Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules
May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has…
Read More
Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease
May 24, 2022
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
May 24, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S…
Read More
A specific protein in blood vessel cells plays a major role in the development of vascular and cardiovascular diseases: The presence of too many "thromboxane A2 receptors" hinders the formation of new blood vessels.
May 23, 2022
Researchers Find New Approach to Treating Cardiovascular Diseases
May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and…
Read More
New data from a study of more than 100 million hospitalizations using machine learning augmentation was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions.
May 23, 2022
Nationwide Study of 100 Million Hospitalizations Finds Percutaneous Coronary Intervention is Safe for Cardio-oncology Patients
May 23, 2022 — New data from a study of more than 100 million hospitalizations using machine learning augmentation was…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now